Eradication of tumour cells by successive injections of allogeneic immune and hyperimmune peritoneal cells in a murine lymphoma system

Abstract

Allogeneic C57BL immune and hyperimmune (vs SL2) peritoneal cells are used for eradication of DBA/2 derived SL2 lymphoma cells injected into the peritoneal cavity of DBA/2 mice.

SL2 bearing DBA/2 mice are treated with 3, 5, or 8 successive i.p. injections of 2 × 106 allogeneic C57BL immune or hyperimmune peritoneal macrophages (contaminated with lymphocytes). 2 × 107 SL2 cells could be eradicated successfully with five injections of immune or three injections of hyperimmune C57BL peritoneal cells. This is a ten-fold improvement compared to the result obtained with single injections of immune or hyperimmune peritoneal cells.

The number of injections with immune or hyperimmune cells, time intervals between the injections and the total length of the period of the therapy was important for the result of the therapy.